v3.26.1
Revenue from Contracts with Customers (Tables)
 6 Months Ended
Jun. 30, 2026
Revenue from Contract with Customer [Abstract]  
Schedule of Product Revenue Provision and Allowance Categories
The following tables summarize activity in each of the Company’s product revenue provision and allowance categories for the six months ended June 30, 2026 and 2025:
Rebates and
Incentives (1)
Product
Returns (2)
Trade
Allowances and
Chargebacks (3)
Balance as of December 31, 2025$170,592 $147,674 $32,150 
Provision related to current period sales291,741 38,573 116,235 
Liability acquired from Azstarys Acquisition45,914 35,371 9,638 
Changes in estimate related to prior period sales(3,657)(6,400)96 
Credits/payments made(290,089)(22,865)(116,697)
Balance as of June 30, 2026$214,501 $192,353 $41,422 
Rebates and
Incentives (1)
Product
Returns (2)
Trade
Allowances and
Chargebacks (3)
Balance as of December 31, 2024$191,508 $147,134 $38,512 
Provision related to current period sales241,829 34,602 101,430 
Ironshore measurement period adjustments671 (20,316)7 
Changes in estimate related to prior period sales(5,445)(2,238)286 
Credits/payments made(256,156)(20,831)(111,286)
Balance as of June 30, 2025$172,407 $138,351 $28,949 
(1)Provisions for rebates and incentives include managed care rebates, government rebates and co-pay program incentives. Provisions for rebates and incentives are deducted from gross revenues at the time revenues are recognized and are included in accrued rebates, returns and discounts in the Company’s Condensed Consolidated Balance Sheets.
(2)Provisions for product returns are deducted from gross revenues at the time revenues are recognized and are included in accrued rebates, returns and discounts in the Company’s Condensed Consolidated Balance Sheets.
(3)Provisions for trade allowances and chargebacks include distribution service fees, prompt pay discounts, and chargebacks. Trade allowances and chargebacks are deducted from gross revenue at the time revenues are recognized and are recorded as a reduction to accounts receivable in the Company’s Condensed Consolidated Balance Sheets.
Schedule of Disaggregation of Revenue As such, the Company disaggregates its product revenues, net from contracts with customers by product, as disclosed in the table below.
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Belbuca$57,669 $52,600 $110,318 $104,258 
Xtampza ER45,006 52,605 95,775 100,247 
Jornay PM46,058 32,626 84,951 61,165 
Nucynta IR14,356 26,501 40,434 53,918 
Nucynta ER15,723 19,946 33,957 39,632 
Azstarys12,910 — 12,910 — 
Symproic3,020 3,722 7,213 6,537 
Nucynta ER AG2,775 — 4,221 — 
Nucynta IR AG2,361 — 3,619 — 
Total product revenues, net$199,878 $188,000 $393,398 $365,757